Kymera Therapeutics (KYMR) Non-Current Deferred Tax Liability (2022 - 2023)
Kymera Therapeutics' (KYMR) quarterly Non-Current Deferred Tax Liability came in at $68.3 million in Q4 2023, up 87.57% year-on-year from $36.4 million in Q4 2022, and up 87.57% on a QoQ basis from $36.4 million in Q4 2022.
Kymera Therapeutics (KYMR) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Kymera Therapeutics (KYMR) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $68.3 million in Q4 2023.
- On a quarterly basis, Non-Current Deferred Tax Liability rose 87.57% year-over-year to $68.3 million in Q4 2023; TTM through Dec 2023 was $68.3 million, a 87.57% increase from a year earlier, with the FY2023 full-year figure at $68.3 million, up 87.57% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2023 stood at $68.3 million, up from $36.4 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for KYMR reached as high as $68.3 million in Q4 2023 and fell as low as $36.4 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 68.34 Mn |
| Dec 31, 2023 | 68.34 Mn |
| Dec 31, 2022 | 36.44 Mn |
| Dec 31, 2022 | 36.44 Mn |